{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:46:21Z","timestamp":1788345981050,"version":"build-2803163510"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T00:00:00Z","timestamp":1580342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Anti-D immunoglobulin (Anti-D Ig) prophylaxis prevents haemolytic disease of the fetus and newborn. Monoclonal IgG anti-Ds (mAb-Ds) would enable unlimited supplies but have differed in efficacy in Fc\u03b3RIIIa-mediated ADCC assays and clinical trials. Structural variations of the oligosaccharide chains of mAb-Ds are hypothesised to be responsible. Quantitative data on 12 Fc-glycosylation features of 23 mAb-Ds (12 clones, 5 produced from multiple cell lines) and one blood donor-derived anti-D Ig were obtained by HPLC and mass spectrometry using 3 methods. Glycosylation of mAb-Ds from human B-lymphoblastoid cell lines (B) was similar to anti-D Ig although fucosylation varied, affecting ADCC activity.\n                    <jats:italic>In vivo<\/jats:italic>\n                    , two B mAb-Ds with 77\u201381% fucosylation cleared red cells and prevented D-immunisation but less effectively than anti-D Ig. High fucosylation (&gt;89%) of mouse-human heterohybridoma (HH) and Chinese hamster ovary (CHO) mAb-Ds blocked ADCC and clearance. Rat YB2\/0 mAb-Ds with &lt;50% fucosylation mediated more efficient ADCC and clearance than anti-D Ig. Galactosylation of B mAb-Ds was 57\u201383% but 15\u201358% for rodent mAb-Ds. HH mAb-Ds had non-human sugars. These data reveal high galactosylation like anti-D Ig (&gt;60%) together with lower fucosylation (&lt;60%) as safe features of mAb-Ds for mediating rapid red cell clearance at low doses, to enable effective, inexpensive prophylaxis.\n                  <\/jats:p>","DOI":"10.1038\/s41598-019-57393-9","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T06:02:57Z","timestamp":1580364177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Anti-D monoclonal antibodies from 23 human and rodent cell lines display diverse IgG Fc-glycosylation profiles that determine their clinical efficacy"],"prefix":"10.1038","volume":"10","author":[{"given":"Belinda M.","family":"Kumpel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radka","family":"Saldova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolien A. M.","family":"Koeleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodie L.","family":"Abrahams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1689-0442","authenticated-orcid":false,"given":"Agnes Hipgrave","family":"Ederveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn L.","family":"Armour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia I.","family":"Olovnikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5621-003X","authenticated-orcid":false,"given":"Gestur","family":"Vidarsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1608-876X","authenticated-orcid":false,"given":"Rick","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline M.","family":"Rudd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0814-4995","authenticated-orcid":false,"given":"Manfred","family":"Wuhrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,30]]},"reference":[{"key":"57393_CR1","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1056\/NEJM199812103392410","volume":"334","author":"JM Bowman","year":"1998","unstructured":"Bowman, J. M. RhD haemolytic disease of the newborn. N. Engl. J. Med. 334, 1775\u20131757 (1998).","journal-title":"N. Engl. J. Med."},{"key":"57393_CR2","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/S2352-4642(18)30071-3","volume":"2","author":"A Zipursky","year":"2018","unstructured":"Zipursky, A., Bhutani, V. K. & Odame, I. Rhesus disease: a global prevention strategy. Lancet Child. Adolesc. Health. 2, 536\u2013542 (2018).","journal-title":"Lancet Child. Adolesc. Health."},{"issue":"(Suppl 1","key":"57393_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/pr.2013.208","volume":"74","author":"VK Bhutani","year":"2013","unstructured":"Bhutani, V. K. et al. Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels. Pediatr. Res. 74((Suppl 1), 86\u2013100 (2013).","journal-title":"Pediatr. Res."},{"key":"57393_CR4","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1134\/S0006297913120092","volume":"78","author":"NI Olovnikova","year":"2013","unstructured":"Olovnikova, N. I. Is an expression system for producing therapeutic antibodies with immunosuppressive properties found at last? Comment to letter by Dr. Quagliaroli. Biochemistry (Mosc.) 78, 1374\u20131375 (2013).","journal-title":"Biochemistry (Mosc.)"},{"key":"57393_CR5","first-page":"410","volume":"12","author":"S Dajak","year":"2014","unstructured":"Dajak, S., Roje, D., Ha\u015dpl, \u017d. H. & Magli\u0107, P. E. The importance of antenatal prevention of RhD immunisation in the first pregnancy. Blood Transfus. 12, 410\u2013415 (2014).","journal-title":"Blood Transfus."},{"key":"57393_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1136\/bmj.300.6720.313","volume":"300","author":"LAD Tovey","year":"1990","unstructured":"Tovey, L. A. D. ABC of Transfusion. Haemolytic disease of the newborn and its prevention. Br. Med. J. 300, 313\u2013316 (1990).","journal-title":"Br. Med. J."},{"issue":"6720","key":"57393_CR7","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/j.1365-2141.1966.tb05636.x","volume":"12","author":"JC Woodrow","year":"1966","unstructured":"Woodrow, J. C. & Finn, R. Transplacental haemorrhage. Br. J. Haematol. 12(6720), 297\u2013309 (1966).","journal-title":"Br. J. Haematol."},{"key":"57393_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000461472","volume":"51","author":"JM Bowman","year":"1986","unstructured":"Bowman, J. M., Pollock, J. M. & Penston, L. E. Fetomaternal transplacental hemorrhage during pregnancy and after delivery. Vox Sang. 51, 117\u2013121 (1986).","journal-title":"Vox Sang."},{"key":"57393_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(59)92264-0","volume":"1","author":"A Zipursky","year":"1959","unstructured":"Zipursky, A., Hull, A., White, F. D. & Israels, L. G. Foetal erythrocytes in the maternal circulation. Lancet 1, 451\u2013452 (1959).","journal-title":"Lancet"},{"key":"57393_CR10","doi-asserted-by":"publisher","first-page":"5949","DOI":"10.4049\/jimmunol.178.9.5949","volume":"178","author":"SJ Germain","year":"2007","unstructured":"Germain, S. J., Sacks, G. P., Sooranna, S. R., Sargent, I. L. & Redman, C. W. Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles. J. Immunol. 178, 5949\u20135956 (2007).","journal-title":"J. Immunol."},{"key":"57393_CR11","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.placenta.2017.06.004","volume":"60","author":"C G\u00f6hner","year":"2017","unstructured":"G\u00f6hner, C., Pl\u00f6sch, T. & Faas, M. M. Immune-modulatory effects of syncytiotrophoblast extracellular vesicles in pregnancy and preeclampsia. Placenta 60, S41\u2013S51 (2017).","journal-title":"Placenta"},{"key":"57393_CR12","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3389\/fimmu.2014.00196","volume":"5","author":"A Schumacher","year":"2014","unstructured":"Schumacher, A., Costa, S.-D. & Zenclussen, A. C. Endocrine factors modulating immune responses in pregnancy. Front. Immunol. 5, 196 (2014).","journal-title":"Front. Immunol."},{"key":"57393_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1423-0410.2011.01533.x","volume":"102","author":"BM Kumpel","year":"2012","unstructured":"Kumpel, B. M. & Manoussaka, M. S. Placental immunology and maternal alloimmune responses. Vox Sang. 102, 2\u201312 (2012).","journal-title":"Vox Sang."},{"key":"57393_CR14","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/j.1365-2141.1965.tb06609.x","volume":"11","author":"PL Mollison","year":"1965","unstructured":"Mollison, P. L., Crome, P., Hughes-Jones, N. C. & Rochna, E. Rate of removal from the circulation of red cells sensitized with different amounts of antibody. Br. J. Haematol. 11, 461\u2013470 (1965).","journal-title":"Br. J. Haematol."},{"key":"57393_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1365-2141.1957.tb05779.x","volume":"3","author":"NC Hughes-Jones","year":"1957","unstructured":"Hughes-Jones, N. C., Mollison, P. L. & Veall, N. Removal of incompatible red cells by the spleen. Br. J. Haematol. 3, 125\u2013133 (1957).","journal-title":"Br. J. Haematol."},{"key":"57393_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-3148.1992.tb00128.x","volume":"2","author":"CP Engelfriet","year":"1992","unstructured":"Engelfriet, C. P. The immune destruction of red cells. Transfus. Med. 2, 1\u20136 (1992).","journal-title":"Transfus. Med."},{"key":"57393_CR17","doi-asserted-by":"publisher","first-page":"e109463","DOI":"10.1371\/journal.pone.0109463","volume":"9","author":"KL Armour","year":"2014","unstructured":"Armour, K. L. et al. Clearance of human IgG1-sensitised red blood cells in vivo in humans relates to the in vitro properties of antibodies from alternative cell lines. PLoS One 9, e109463 (2014).","journal-title":"PLoS One"},{"key":"57393_CR18","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1111\/j.1537-2995.2006.00924_1.x","volume":"46","author":"BM Kumpel","year":"2006","unstructured":"Kumpel, B. M. On the immunologic basis of Rh immune globulin (anti-D) prophylaxis. Transfusion 46, 1652\u20131656 (2006).","journal-title":"Transfusion"},{"key":"57393_CR19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1423-0410.2007.00945.x","volume":"93","author":"BM Kumpel","year":"2007","unstructured":"Kumpel, B. M. Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers. Vox Sang. 93, 99\u2013111 (2007).","journal-title":"Vox Sang."},{"key":"57393_CR20","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1002\/eji.1830191216","volume":"19","author":"BM Kumpel","year":"1989","unstructured":"Kumpel, B. M. et al. Heterogeneity in the ability of IgG1 monoclonal anti-D to promote lymphocyte-mediated red cell lysis. Eur. J. Immunol. 19, 2283\u20132288 (1989).","journal-title":"Eur. J. Immunol."},{"key":"57393_CR21","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1021\/bi00378a023","volume":"26","author":"N Takahashi","year":"1987","unstructured":"Takahashi, N. et al. Comparative structural study of the N-linked oligosaccharides of human normal and pathological immunoglobulin G. Biochemistry 26, 1137\u20131144 (1987).","journal-title":"Biochemistry"},{"key":"57393_CR22","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1182\/blood-2013-09-527978","volume":"123","author":"R Kapur","year":"2014","unstructured":"Kapur, R. et al. A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy. Blood 123, 471\u2013480 (2014).","journal-title":"Blood"},{"key":"57393_CR23","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/bjh.12965","volume":"166","author":"R Kapur","year":"2014","unstructured":"Kapur, R. et al. Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn. Br. J. Haematol. 166, 936\u2013945 (2014).","journal-title":"Br. J. Haematol."},{"key":"57393_CR24","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/bjh.14438","volume":"176","author":"ME Sonneveld","year":"2017","unstructured":"Sonneveld, M. E. et al. Antigen specificity determines anti-red blood cell IgG-Fc alloantibody glycosylation and thereby severity of haemolytic disease of the fetus and newborn. Br. J. Haematol. 176, 651\u2013660 (2017).","journal-title":"Br. J. Haematol."},{"key":"57393_CR25","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/trf.12880","volume":"55","author":"R Kapur","year":"2015","unstructured":"Kapur, R. et al. Prophylactic anti-D preparations display variable decreases in Fc-fucosylation of anti-D. Transfusion 55, 553\u2013562 (2015).","journal-title":"Transfusion"},{"key":"57393_CR26","doi-asserted-by":"publisher","first-page":"e0139828","DOI":"10.1371\/journal.pone0139828","volume":"10","author":"WJ Fokkink","year":"2015","unstructured":"Fokkink, W. J. et al. Comparison of Fc N-glycosylation of pharmaceutical products of intravenous immunoglobulin G. PLoS One 10, e0139828, https:\/\/doi.org\/10.1371\/journal.pone0139828 (2015).","journal-title":"PLoS One"},{"key":"57393_CR27","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1600-0412.2012.01377.x","volume":"91","author":"E Tiblad","year":"2012","unstructured":"Tiblad, E., Wikman, A., Rane, A., Jansson, Y. & Westgren, M. Pharmacokinetics of 250 \u03bcg anti-D IgG in the third trimester of pregnancy: an observational study. Acta Obstet. Gynecol. Scand. 91, 587\u2013592 (2012).","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"57393_CR28","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1182\/blood-2005-03-0989","volume":"107","author":"KL Armour","year":"2006","unstructured":"Armour, K. L. et al. Intravascular survival of red cells coated with a mutated human anti-D antibody engineered to lack destructive activity. Blood 107, 2619\u20132626 (2006).","journal-title":"Blood"},{"key":"57393_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1365-2141.2008.06985.x","volume":"141","author":"R Beliard","year":"2008","unstructured":"Beliard, R. et al. A human anti-D monoclonal antibody selected for enhanced Fc\u03b3RIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies. Br. J. Haematol. 141, 109\u2013119 (2008).","journal-title":"Br. J. Haematol."},{"key":"57393_CR30","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/0140-6736(90)92767-C","volume":"336","author":"A Thomson","year":"1990","unstructured":"Thomson, A. et al. Clearance of Rh D-positive red cells with monoclonal anti-D. Lancet 336, 1147\u20131150 (1990).","journal-title":"Lancet"},{"key":"57393_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/j.1365-2249.2007.03458.x","volume":"150","author":"GE Chapman","year":"2007","unstructured":"Chapman, G. E. et al. The clearance kinetics of autologous RhD-positive erythrocytes coated ex vivo with novel recombinant and monoclonal anti-D antibodies. Clin. Exp. Immunol. 150, 30\u201341 (2007).","journal-title":"Clin. Exp. Immunol."},{"key":"57393_CR32","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/(SICI)1521-4141(199908)29:08<2613::AID-IMMU2613>3.0.CO;2-J","volume":"29","author":"KL Armour","year":"1999","unstructured":"Armour, K. L., Clark, M. R., Hadley, A. G. & Williamson, L. M. Recombinant human IgG molecules lacking Fc gamma receptor I binding and monocyte triggering activities. Eur. J. Immunol. 29, 2613\u20132624 (1999).","journal-title":"Eur. J. Immunol."},{"key":"57393_CR33","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1182\/blood.V86.5.1701.bloodjournal8651701","volume":"86","author":"BM Kumpel","year":"1995","unstructured":"Kumpel, B. M. et al. Human Rh D monoclonal antibodies (BRAD-3 and BRAD-5) cause accelerated clearance of Rh D+ red blood cells and suppression of Rh D immunization in Rh D- volunteers. Blood 86, 1701\u20131709 (1995).","journal-title":"Blood"},{"issue":"Suppl. 1","key":"57393_CR34","first-page":"8","volume":"10","author":"NA Smith","year":"2000","unstructured":"Smith, N. A. et al. A multi-centre trial of monoclonal anti-D in the prevention of Rh-immunisation of RhD- male volunteers by RhD+ red cells. Transfus. Med. 10(Suppl. 1), 8 (2000).","journal-title":"Transfus. Med."},{"key":"57393_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S1246-7820(01)00209-9","volume":"9","author":"BM Kumpel","year":"2002","unstructured":"Kumpel, B. M. In vivo studies of monoclonal anti-D and the mechanism of immune suppression. Transfus. Clin. Biol. 9, 9\u201314 (2002).","journal-title":"Transfus. Clin. Biol."},{"key":"57393_CR36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.tracli.2006.03.013","volume":"13","author":"R B\u00e9liard","year":"2006","unstructured":"B\u00e9liard, R. Monoclonal antibodies to prevent alloimmunization: lessons from clinical trials. Transfus. Clin. Biol. 13, 58\u201364 (2006).","journal-title":"Transfus. Clin. Biol."},{"key":"57393_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/BF02433872","volume":"129","author":"NI Olovnikova","year":"2000","unstructured":"Olovnikova, N. I. et al. Rapid clearance of Rhesus-positive erythrocytes with monoclonal anti-Rhesus antibodies is insufficient for effective prevention of Rhesus sensitization. Bull. Exp. Biol. Med. 129, 77\u201381 (2000).","journal-title":"Bull. Exp. Biol. Med."},{"key":"57393_CR38","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1182\/blood-2003-11-3929","volume":"103","author":"S Miescher","year":"2004","unstructured":"Miescher, S. et al. A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the Fc\u03b3RIIA and Fc\u03b3RIIIA genes. Blood 103, 4028\u20134035 (2004).","journal-title":"Blood"},{"key":"57393_CR39","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.4049\/jimmunol.157.11.4963","volume":"157","author":"J Lund","year":"1996","unstructured":"Lund, J., Takahashi, N., Pound, J. D., Goodall, M. & Jefferis, R. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharides. J. Immunol. 157, 4963\u20134969 (1996).","journal-title":"J. Immunol."},{"key":"57393_CR40","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1021\/bi9621472","volume":"36","author":"MR Wormald","year":"1997","unstructured":"Wormald, M. R. et al. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides. Biochemistry 36, 1370\u20131380 (1997).","journal-title":"Biochemistry"},{"key":"57393_CR41","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/S0022-2836(02)01250-0","volume":"325","author":"S Krapp","year":"2003","unstructured":"Krapp, S., Mimura, Y., Jefferis, R., Huber, R. & Sondermann, P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J. Mol. Biol. 325, 979\u2013989 (2003).","journal-title":"J. Mol. Biol."},{"key":"57393_CR42","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/35018508","volume":"406","author":"P Sondermann","year":"2000","unstructured":"Sondermann, P., Huber, R., Oosthuizen, V. & Jacob, U. The 3.2-\u00c5 crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. Nature 406, 267\u2013273 (2000).","journal-title":"Nature"},{"key":"57393_CR43","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1021\/acs.biochem.5b00299","volume":"54","author":"QM Hansom","year":"2015","unstructured":"Hansom, Q. M. & Barb, A. W. A perspective on the structure and receptor-binding properties of immunoglobulin G Fc. Biochemistry 54, 2931\u20132942 (2015).","journal-title":"Biochemistry"},{"key":"57393_CR44","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1046\/j.1365-2141.1996.d01-1764.x","volume":"94","author":"BM Kumpel","year":"1996","unstructured":"Kumpel, B. M. et al. Antigen topography is critical for interaction of IgG2 anti-red-cell antibodies with Fc\u03b3 receptors. Br. J. Haematol. 94, 175\u2013183 (1996).","journal-title":"Br. J. Haematol."},{"key":"57393_CR45","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1073\/pnas.1711720115","volume":"115","author":"FS van de Bovenkamp","year":"2018","unstructured":"van de Bovenkamp, F. S. et al. Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region. Proc. Natl. Acad. Sci. USA 115, 1901\u20131906 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"57393_CR46","doi-asserted-by":"publisher","first-page":"26733","DOI":"10.1074\/jbc.M202069200","volume":"277","author":"RL Shields","year":"2002","unstructured":"Shields, R. L. et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fc\u03b3RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277, 26733\u201326740 (2002).","journal-title":"J. Biol. Chem."},{"key":"57393_CR47","doi-asserted-by":"publisher","first-page":"12669","DOI":"10.1073\/pnas.1108455108","volume":"108","author":"C Ferrara","year":"2011","unstructured":"Ferrara, C. et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc\u03b3RIII and antibodies lacking core fucose. Proc. Natl. Acad. Sci. USA 108, 12669\u201312674 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"57393_CR48","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1158\/1078-0432.CCR-05-2619","volume":"12","author":"S Iida","year":"2006","unstructured":"Iida, S. et al. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. Clin. Cancer Res. 12, 2879\u20132887 (2006).","journal-title":"Clin. Cancer Res."},{"key":"57393_CR49","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1134\/S0006297912080147","volume":"77","author":"NI Olovnikova","year":"2012","unstructured":"Olovnikova, N. I., Ershler, M. A., Grigorieva, O. V., Petrov, A. V. & Miterev, G. Y. Impact on N-glycosylation profile of monoclonal anti-D antibodies as a way to control their immunoregulatory and cytotoxic properties. Biochemistry (Mosc.) 77, 925\u2013933 (2012).","journal-title":"Biochemistry (Mosc.)"},{"key":"57393_CR50","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1246-7820(01)00215-4","volume":"9","author":"BM Kumpel","year":"2002","unstructured":"Kumpel, B. M. et al. Section 1C: Assessment of the functional activity and IgG Fc receptor utilisation of 64 IgG Rh monoclonal antibodies. Coordinator\u2019s report. Transfus. Clin. Biol. 9, 45\u201353 (2002).","journal-title":"Transfus. Clin. Biol."},{"key":"57393_CR51","doi-asserted-by":"publisher","DOI":"10.5772\/28744","volume-title":"Immunosuppression - Role in Health and Diseases","author":"Natalia Olovnikova","year":"2012","unstructured":"Olovnikova, N. Anti-RhD-Mediated Immunosuppression: Can Monoclonal Antibodies Imitate the Action of Polyclonal Antibodies? (eds. Kapur, S. & Portela, M.B.) Immunosuppression - Role in Health and Diseases. 77\u2013106, https:\/\/doi.org\/10.5772\/28744, https:\/\/www.intechopen.com\/books\/immunosuppression-role-in-health-and-diseases\/anti-rhd-mediated-immunosuppression-can-monoclonal-antibodies-imitate-the-action-of-polyclonal-antib (InTech: Rijeka, Croatia, 2012)."},{"key":"57393_CR52","doi-asserted-by":"publisher","first-page":"e89703","DOI":"10.1172\/jci.insight89703","volume":"2","author":"A Ercan","year":"2017","unstructured":"Ercan, A. et al. Estrogens regulate glycosylation of IgG in women and men. JCI Insight 2, e89703, https:\/\/doi.org\/10.1172\/jci.insight89703 (2017).","journal-title":"JCI Insight"},{"key":"57393_CR53","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/0896-8411(91)90173-A","volume":"4","author":"GA Rook","year":"1991","unstructured":"Rook, G. A. et al. Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. J. Autoimmun. 4, 779\u2013794 (1991).","journal-title":"J. Autoimmun."},{"key":"57393_CR54","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.1021\/pr400589m","volume":"12","author":"A Bondt","year":"2013","unstructured":"Bondt, A. et al. Association between galactosylation of immunoglobulin G and improvement of rheumatoid arthritis during pregnancy is independent of sialylation. J. Proteome Res. 12, 4522\u20134531 (2013).","journal-title":"J. Proteome Res."},{"key":"57393_CR55","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/316452a0","volume":"316","author":"RB Parekh","year":"1985","unstructured":"Parekh, R. B. et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 316, 452\u2013457 (1985).","journal-title":"Nature"},{"key":"57393_CR56","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3899\/jrheum.110584","volume":"39","author":"LN Troelsen","year":"2012","unstructured":"Troelsen, L. N. et al. IgG glycosylation changes and MBL2 polymorphisms: association with markers of systemic inflammation and joint destruction in rheumatoid arthritis. J. Rheumatol. 39, 463\u2013469 (2012).","journal-title":"J. Rheumatol."},{"key":"57393_CR57","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/rheumatology\/ket189","volume":"52","author":"ES Collins","year":"2013","unstructured":"Collins, E. S. et al. Glycosylation status of serum in inflammatory arthritis in response to anti-TNF treatment. Rheumatology (Oxford) 52, 1572\u20131582 (2013).","journal-title":"Rheumatology (Oxford)"},{"key":"57393_CR58","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1021\/pr500780a","volume":"14","author":"M Wuhrer","year":"2015","unstructured":"Wuhrer, M. et al. Skewed Fc glycosylation profiles of anti-proteinase 3 immunoglobulin G1 autoantibodies from granulomatosis with polyangiitis patients show low levels of bisection, galactosylation and sialylation. J. Proteome Res. 14, 1657\u20131665 (2015).","journal-title":"J. Proteome Res."},{"key":"57393_CR59","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3233\/HAB-1995-6301","volume":"6","author":"BM Kumpel","year":"1995","unstructured":"Kumpel, B. M., Wang, Y., Griffiths, H. L., Hadley, A. G. & Rook, G. A. The biological activity of human monoclonal IgG anti-D is reduced by \u03b2-galactosidase treatment. Hum. Antibodies Hybridomas 6, 82\u201388 (1995).","journal-title":"Hum. Antibodies Hybridomas"},{"key":"57393_CR60","doi-asserted-by":"publisher","first-page":"e0134949","DOI":"10.1371\/journal.pone0134949","volume":"10","author":"M Thomann","year":"2015","unstructured":"Thomann, M. et al. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity. PLoS One 10, e0134949, https:\/\/doi.org\/10.1371\/journal.pone0134949 (2015).","journal-title":"PLoS One"},{"key":"57393_CR61","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3389\/fimmu00877","volume":"8","author":"G Dekkers","year":"2017","unstructured":"Dekkers, G. et al. Decoding the human immunoglobulin G-glycan repertoire reveals a spectrum of Fc-receptor- and complement-mediated-effector activities. Front. Immunol. 8, 877, https:\/\/doi.org\/10.3389\/fimmu00877 (2017).","journal-title":"Front. Immunol."},{"key":"57393_CR62","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1182\/blood-2014-05-576835","volume":"124","author":"SQ Nagelkerke","year":"2014","unstructured":"Nagelkerke, S. Q. et al. Inhibition of Fc\u03b3R-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and Fc\u03b3RIIb in human macrophages. Blood 124, 3709\u20133718 (2014).","journal-title":"Blood"},{"key":"57393_CR63","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/glycob\/10.5.477","volume":"10","author":"TS Raju","year":"2000","unstructured":"Raju, T. S., Briggs, J. B., Borge, S. M. & Jones, A. J. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 10, 477\u2013486 (2000).","journal-title":"Glycobiology"},{"key":"57393_CR64","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/glycob\/cwn072","volume":"18","author":"V Padler-Karavani","year":"2008","unstructured":"Padler-Karavani, V. et al. Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology 18, 818\u2013830 (2008).","journal-title":"Glycobiology"},{"key":"57393_CR65","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/6179","volume":"17","author":"P Uma\u00f1a","year":"1999","unstructured":"Uma\u00f1a, P., Jean-Mairet, J., Moudry, R., Amstutz, H. & Bailey, J. E. Engineered glycoforms of an antineuroblastoma IgG1 with optimised antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17, 176\u2013180 (1999).","journal-title":"Nat. Biotechnol."},{"key":"57393_CR66","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/bit.1119","volume":"74","author":"J Davies","year":"2001","unstructured":"Davies, J. et al. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol. Bioeng. 74, 288\u2013294 (2001).","journal-title":"Biotechnol. Bioeng."},{"key":"57393_CR67","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/j.1440-1711.2005.01366.x","volume":"83","author":"U Galili","year":"2005","unstructured":"Galili, U. The \u03b1-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. Immunol. Cell Biol. 83, 674\u2013686 (2005).","journal-title":"Immunol. Cell Biol."},{"key":"57393_CR68","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1182\/blood.V82.8.2485.2485","volume":"82","author":"U Galili","year":"1993","unstructured":"Galili, U., Anaraki, F., Thall, A., Hill-Black, C. & Radic, M. One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. Blood 82, 2485\u20132493 (1993).","journal-title":"Blood"},{"key":"57393_CR69","first-page":"152","volume":"5","author":"RF Monta\u00f1o","year":"1994","unstructured":"Monta\u00f1o, R. F. & Romano, E. L. Human monoclonal anti-Rh antibodies produced by human-mouse heterohybridomas express the Gal \u03b11-3 Gal epitope. Hum. Antibodies Hybridomas 5, 152\u2013156 (1994).","journal-title":"Hum. Antibodies Hybridomas"},{"key":"57393_CR70","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/nbt.1651","volume":"28","author":"D Ghaderi","year":"2010","unstructured":"Ghaderi, D., Taylor, R., Padler-Karavani, V., Diaz, S. & Varki, A. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat. Biotechnol. 28, 863\u2013867 (2010).","journal-title":"Nat. Biotechnol."},{"key":"57393_CR71","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000461366","volume":"61","author":"BD Gorick","year":"1991","unstructured":"Gorick, B. D. & Hughes-Jones, N. C. Relative functional binding activity of IgG1 and IgG3 anti-D in IgG preparations. Vox Sang. 61, 251\u2013254 (1991).","journal-title":"Vox Sang."},{"key":"57393_CR72","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1046\/j.1423-0410.1997.00045.x","volume":"72","author":"BM Kumpel","year":"1997","unstructured":"Kumpel, B. M. In vitro functional activity of IgG1 and IgG3 polyclonal and monoclonal anti-D. Vox Sang. 72, 45\u201351 (1997).","journal-title":"Vox Sang."},{"issue":"Suppl.2","key":"57393_CR73","first-page":"20","volume":"6","author":"BM Kumpel","year":"1996","unstructured":"Kumpel, B. M. & Davenport, R. D. Comparison of two Fc\u03b3RIII-mediated assays of anti-D functional activity, using spleen and K cells. Transfus. Med. 6(Suppl.2), 20 (1996).","journal-title":"Transfus. Med."},{"key":"57393_CR74","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.4049\/jimmunol.159.8.3849","volume":"159","author":"JC Edberg","year":"1997","unstructured":"Edberg, J. C. & Kimberly, R. P. Cell type-specific glycoforms of Fc gamma RIIIa (CD16): differential ligand binding. J. Immunol. 159, 3849\u20133857 (1997).","journal-title":"J. Immunol."},{"key":"57393_CR75","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1182\/bloodadvances.2017015008","volume":"2","author":"SQ Nagelkerke","year":"2018","unstructured":"Nagelkerke, S. Q. et al. Red pulp macrophages in the human spleen are a distinct cell population with a unique expression of Fc-\u03b3 receptors. Blood Adv. 2, 941\u2013953 (2018).","journal-title":"Blood Adv."},{"key":"57393_CR76","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S1471-4906(00)01801-9","volume":"22","author":"BM Kumpel","year":"2001","unstructured":"Kumpel, B. M. & Elson, C. J. Mechanism of anti-D-mediated immune suppression \u2013 a paradox awaiting resolution? Trends Immunol. 22, 26\u201331 (2001).","journal-title":"Trends Immunol."},{"key":"57393_CR77","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/bmj.4.5992.320","volume":"4","author":"LA Tovey","year":"1975","unstructured":"Tovey, L. A. & Robinson, A. E. Reduced severity of Rh-haemolytic disease after anti-D immunoglobulin. Brit. Med. J. 4, 320\u2013322 (1975).","journal-title":"Brit. Med. J."},{"key":"57393_CR78","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1136\/bmj.298.6689.1671","volume":"298","author":"JG Thornton","year":"1989","unstructured":"Thornton, J. G. et al. Efficacy and long term effects of antenatal prophylaxis with anti-D immunoglobulin. Brit. Med. J. 298, 1671\u20131673 (1989).","journal-title":"Brit. Med. J."},{"key":"57393_CR79","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1111\/j.1537-2995.2008.01742.x","volume":"48","author":"JM Koelewijn","year":"2008","unstructured":"Koelewijn, J. M., de Haas, M., Vrijkotte, T. G., Bonsel, G. J. & van der Schoot, C. E. One single dose of 200 ug of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy. Transfusion 48, 1721\u20131729 (2008).","journal-title":"Transfusion"},{"key":"57393_CR80","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1046\/j.1365-3148.1999.00217.x","volume":"9","author":"A Lubenko","year":"1999","unstructured":"Lubenko, A. et al. Monitoring the clearance of fetal RhD-positive red cells in FMH following RhD immunoglobulin administration. Transfus. Med. 9, 331\u2013335 (1999).","journal-title":"Transfus. Med."},{"key":"57393_CR81","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1136\/bmj.2.5962.57","volume":"2","author":"JC Woodrow","year":"1975","unstructured":"Woodrow, J. C. et al. Mechanism of Rh prophylaxis: an experimental study on specificity of immunosuppression. Brit. Med. J. 2, 57\u201359 (1975).","journal-title":"Brit. Med. J."},{"key":"57393_CR82","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.clim.2005.10.008","volume":"118","author":"S Siberil","year":"2006","unstructured":"Siberil, S. et al. Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc\u03b3R functions. Clin. Immunol. 118, 170\u2013179 (2006).","journal-title":"Clin. Immunol."},{"key":"57393_CR83","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/j.1537-2995.2010.02905.x","volume":"51","author":"DR Branch","year":"2010","unstructured":"Branch, D. R., Scofield, T. L., Moulds, J. J. & Swanson, J. L. Unexpected suppression of anti-Fya and prevention of hemolytic disease of the fetus and newborn after administration of Rh immune globulin. Transfusion 51, 816\u2013819 (2010).","journal-title":"Transfusion"},{"key":"57393_CR84","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1111\/trf.12049","volume":"53","author":"RM Kaufman","year":"2013","unstructured":"Kaufman, R. M., Schlumpf, K. S., Wright, D. J. & Triulzi, D. J. Does Rh immune globulin suppress HLA sensitization in pregnancy? Transfusion 53, 2069\u20132077 (2013).","journal-title":"Transfusion"},{"key":"57393_CR85","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1046\/j.1537-2995.1990.30290162897.x","volume":"30","author":"CM Giles","year":"1990","unstructured":"Giles, C. M., Botto, M. & King, M. J. A study of HLA (Bg) on red cells and platelets by immunoblotting with monoclonal antibodies. Transfusion 30, 126\u2013132 (1990).","journal-title":"Transfusion"},{"key":"57393_CR86","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/0167-5699(93)90235-D","volume":"14","author":"TG Wegmann","year":"1993","unstructured":"Wegmann, T. G., Lin, H., Guilbert, L. & Mossman, T. R. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol. Today 14, 353\u2013356 (1993).","journal-title":"Immunol. Today"},{"key":"57393_CR87","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1111\/j.1537-2995.2006.00946.x","volume":"46","author":"JE Hendrickson","year":"2006","unstructured":"Hendrickson, J. E. et al. Recipient inflammation affects the frequency and magnitude of immunization to transfused red blood cells. Transfusion 46, 1526\u20131536 (2006).","journal-title":"Transfusion"},{"key":"57393_CR88","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1182\/blood-2004-11-4303","volume":"106","author":"AR Gaines","year":"2005","unstructured":"Gaines, A. R. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinurea following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 106, 1532\u20131537 (2005).","journal-title":"Blood"},{"key":"57393_CR89","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1182\/blood-2003-04-1029","volume":"102","author":"MD Coopamah","year":"2003","unstructured":"Coopamah, M. D., Freedman, J. & Semple, J. W. Anti-D initially stimulates an Fc-dependent leukocyte oxidative burst and subsequently suppresses erythrophagocytosis via interleukin-1 receptor antagonist. Blood 102, 2862\u20132867 (2003).","journal-title":"Blood"},{"key":"57393_CR90","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/j.1537-2995.2006.00898.x","volume":"46","author":"DR Branch","year":"2006","unstructured":"Branch, D. R., Shabani, F., Lund, N. & Denomme, G. A. Antenatal administration of Rh immune globulin causes significant increases in the immunomodulatory cytokines Transforming Growth Factor beta1 and prostaglandin E2. Transfusion 46, 1316\u20131322 (2006).","journal-title":"Transfusion"},{"key":"57393_CR91","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1136\/bmj.2.5519.907","volume":"2","author":"CA Clarke","year":"1966","unstructured":"Clarke, C. A. et al. Prevention of Rh-haemolytic disease: results of the clinical trial (1966). A combined study from centres in England and Baltimore. Brit. Med. J. 2, 907\u2013914 (1966).","journal-title":"Brit. Med. J."},{"key":"57393_CR92","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1136\/bmj.1.5696.593","volume":"1","author":"HH Gunson","year":"1970","unstructured":"Gunson, H. H., Stratton, F., Cooper, D. G. & Rawlinson, V. I. Primary immunization of Rh-negative volunteers. Br. Med. J. 1, 593\u2013595 (1970).","journal-title":"Br. Med. J."},{"key":"57393_CR93","first-page":"349","volume":"17","author":"JC Woodrow","year":"1969","unstructured":"Woodrow, J. C., Finn, R. & Krevans, J. R. Rapid clearance of Rh positive blood during experimental Rh immunization. Vox Sang. 17, 349\u2013361 (1969).","journal-title":"Vox Sang."},{"key":"57393_CR94","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1537-2995.1971.tb04424.x","volume":"11","author":"W Pollack","year":"1971","unstructured":"Pollack, W. et al. Studies on Rh prophylaxis. I. Relationship between doses of anti-Rh and size of antigenic stimulus. Transfusion 11, 333\u2013339 (1971).","journal-title":"Transfusion"},{"key":"57393_CR95","first-page":"734","volume":"12","author":"R Stasi","year":"2010","unstructured":"Stasi, R. Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura. Curr. Opin. Mol. Ther. 12, 734\u2013740 (2010).","journal-title":"Curr. Opin. Mol. Ther."},{"key":"57393_CR96","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1423-0410.2012.01603.x","volume":"103","author":"A Yver","year":"2012","unstructured":"Yver, A. et al. Pharmacokinetics and safety of roledumab, a novel human recombinant monoclonal anti-RhD antibody with an optimised Fc for improved engagement of FC\u03b3RIII, in healthy volunteers. Vox Sang. 103, 213\u2013222 (2012).","journal-title":"Vox Sang."},{"key":"57393_CR97","unstructured":"Laboratoire fran\u00e7ais de Fractionnement et de Biotechnologies. Pharmacokinetics and safety of Roledumab, in RhD-negative pregnant women carrying an RhD-positive foetus. Posted 11th November 2014, study completed 13th September 2017, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02287896. Accessed November 10th, (2019)."},{"key":"57393_CR98","doi-asserted-by":"publisher","first-page":"e0162973","DOI":"10.1371\/journal.pone0162973","volume":"11","author":"YJ Weng","year":"2016","unstructured":"Weng, Y. J. et al. Anti-human platelet antigen-1a immunoglobulin G preparation intended to prevent fetal and neonatal alloimmune thrombocytopenia. PLoS One 11, e0162973, https:\/\/doi.org\/10.1371\/journal.pone0162973 (2016).","journal-title":"PLoS One"},{"key":"57393_CR99","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1046\/j.1537-2995.2001.41060766.x","volume":"41","author":"V Kiefel","year":"2001","unstructured":"Kiefel, V., K\u00f6nig, C., Kroll, H. & Santoso, S. Platelet alloantibodies in transfused patients. Transfusion 41, 766\u2013770 (2001).","journal-title":"Transfusion"},{"key":"57393_CR100","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1046\/j.1423-0410.2003.00259.x","volume":"84","author":"CP Engelfriet","year":"2003","unstructured":"Engelfriet, C. P. & Reesink, H. W. Detection of platelet-reactive antibodies in patients who are refractory to platelet transfusions, and the selection of compatible donors. Vox Sang. 84, 73\u201388 (2003).","journal-title":"Vox Sang."},{"key":"57393_CR101","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1111\/j.1537-2995.2012.03700.x","volume":"52","author":"BM Kumpel","year":"2012","unstructured":"Kumpel, B. M. Would it be possible to prevent HPA-1a alloimmunization to reduce the incidence of fetal and neonatal alloimmune thrombocytopenia? Transfusion 52, 1393\u20131397 (2012).","journal-title":"Transfusion"},{"key":"57393_CR102","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/btpr.92","volume":"25","author":"PH van Berkel","year":"2009","unstructured":"van Berkel, P. H. et al. N-linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG. Biotechnol. Prog. 25, 244\u2013251 (2009).","journal-title":"Biotechnol. Prog."},{"key":"57393_CR103","first-page":"125","volume":"347","author":"L Royle","year":"2006","unstructured":"Royle, L., Radcliffe, C. M., Dwek, R. A. & Rudd, P. M. Detailed structural analysis of N-glycans released from glycoproteins in SDS-PAGE gel bands using HPLC combined with exoglycosidase array digestions. Methods Mol. Biol. 347, 125\u2013143 (2006).","journal-title":"Methods Mol. Biol."},{"key":"57393_CR104","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1021\/ac800630x","volume":"80","author":"LR Ruhaak","year":"2008","unstructured":"Ruhaak, L. R. et al. Hydrophilic interaction chromatography-based high-throughput sample preparation method for N-glycan analysis from total human plasma glycoproteins. Anal. Chem. 80, 6119\u20136126 (2008).","journal-title":"Anal. Chem."},{"key":"57393_CR105","doi-asserted-by":"publisher","first-page":"M111.010090","DOI":"10.1074\/mcpM111.010090","volume":"10","author":"M Puci\u0107","year":"2011","unstructured":"Puci\u0107, M. et al. High throughput isolation and glycosylation analysis of IgG variability and heritability of the IgG glycome in three isolated human populations. Mol. Cell. Proteomics. 10, M111.010090, https:\/\/doi.org\/10.1074\/mcpM111.010090 (2011).","journal-title":"Mol. Cell. Proteomics."},{"key":"57393_CR106","doi-asserted-by":"publisher","first-page":"5784","DOI":"10.1021\/ac500335t","volume":"86","author":"KR Reiding","year":"2014","unstructured":"Reiding, K. R., Blank, D., Kuijper, D. M., Deelder, A. M. & Wuhrer, M. High throughput profiling of protein N-glycosylation by MALDI-TOF-MS employing linkage-specific sialic acid esterification. Anal. Chem. 86, 5784\u20135793 (2014).","journal-title":"Anal. Chem."},{"key":"57393_CR107","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1021\/ac1027116","volume":"83","author":"MH Selman","year":"2011","unstructured":"Selman, M. H., Hemayatkar, M., Deelder, A. M. & Wuhrer, M. Cotton HILIC SPE microtips for microscale purification and enrichment of glycans and glycopeptides. Anal. Chem. 83, 2492\u20132499 (2011).","journal-title":"Anal. Chem."},{"key":"57393_CR108","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jprot.2011.11.003","volume":"75","author":"MH Selman","year":"2012","unstructured":"Selman, M. H. et al. Fc specific IgG glycosylation profiling by robust nano-reverse phase HPLC-MS using a sheath-flow ESI sprayer interface. J. Proteomics 75, 1318\u20131329 (2012).","journal-title":"J. Proteomics"},{"key":"57393_CR109","first-page":"143","volume":"5","author":"BM Kumpel","year":"1994","unstructured":"Kumpel, B. M., Rademacher, T. W., Rook, G. A., Williams, P. J. & Wilson, I. B. Galactosylation of human IgG monoclonal anti-D produced by EBV-transformed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity. Hum. Antibodies Hybridomas 5, 143\u2013151 (1994).","journal-title":"Hum. Antibodies Hybridomas"},{"key":"57393_CR110","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/tme.12091","volume":"24","author":"H Qureshi","year":"2014","unstructured":"Qureshi, H. et al. BCSH guidelines for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. Transfus. Med. 24, 8\u201320 (2014).","journal-title":"Transfus. Med."},{"key":"57393_CR111","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/trf.12484","volume":"54","author":"B Kumpel","year":"2014","unstructured":"Kumpel, B. et al. Accurate quantitation of D+ fetomaternal haemorrhage by flow cytometry using a novel reagent to eliminate granulocytes from analysis. Transfusion. 54, 1305\u20131316 (2014).","journal-title":"Transfusion."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-57393-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-57393-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-57393-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T18:16:24Z","timestamp":1695665784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-57393-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,30]]},"references-count":111,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["57393"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-57393-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,30]]},"assertion":[{"value":"3 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1464"}}